Despite pre-clinical studies suggesting up-regulation of PD-L1 in ALK-rearranged NSCLC, single-agent ICI have not shown clinical benefit in retrospective studies in the treatment of ALK-rearranged NSCLC. Here, ALK is linked to non-small cell lung carcinoma.